Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand		 Sheep,
Cattle		 Granted
New
Zealand		 Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle		 Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle		 Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig		 Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Medi-Solfen® also has the potential to improve patient quality of life

Patients with chronic leg ulcers describe their experience as challenging and difficult. Patients experience their body as unreliable, which in their daily life means that it may be a source of social embarrassment – and possibly eventual isolation due to symptoms such as bad smell, excess of exudate, and pain.1

There are several types of wound pain but of relevance to the use of Medi-Solfen® is the pain type described as “procedural/operative” which is pain that results from routine procedures such as dressing changes or wound cleansing, or is associated with significant wound interventions, such as biopsies or sharp debridement. Sharp debridement of non-viable tissue is a frequent treatment modality for leg ulcers patients. However, the procedure is not well tolerated and patients will often ask the clinicians to stop before the debridement is completed because of the pain2,3,4

It is possible that patients will deny future consent for the sharp debridement if the first experience was painful. This poses difficulties in providing optimal care and in achieving healing in a timely manner. Delayed healing eventually creates additional costs and deterioration in the patient’s quality of life. Debridement procedures are painful not only during the procedure but hours and days after the procedure as well.

The NHS aims at providing patients with a positive experience of the health system, of physical comfort and advocates emotional support and alleviation of fear and anxiety about such issues as clinical status and its treatment5. In this perspective one could say that management of pain is a marker of the quality of care and a way of improving people’s when the wound did not hurt. When patients felt an ease or absence of pain they interpreted it as a positive sign of wound healing, which made them feel hopeful and optimistic6. Pain measurement within the holistic process of quantifying impact on a patient’s quality of life could and probably will become a key goal for future initiatives.

References

  1. Bland, M. (1999) On living with chronic leg ulcers. In Nursing and the Experience of Illness: Phenomenology Practice. Editors: Irena Madjar and Jo Ann Walton. Publishers: Allen & Unwin, pp. 36-56.
  2. Hansson, C., Holm, J., Stefan, L. and Syren, A. (1993) Repeated treatment with lidocaine/prilocaine cream (EMLA) as a topical anaesthetic for the cleansing of venous leg ulcers. Acta Dermato-Venereologica. 73: 231–233.
  3. Enander Malmros I, Nilsen T, Lillieborg S. (1990) Plasma concentrations and analgesic effect of EMLA (Lidocaine/Prilocaine) cream for the cleansing of leg ulcers. Acta Dermato-Venereologica. 70(3): 227–30.
  4. Lok, C. et al (1999) EMLA cream as a topical anaesthetic for the repeated mechanical debridement of venous leg ulcers: a double-blind, placebo-controlled study. Journal of the American Academy of Dermatology. Volume 40, issue 2, pp. 208-213.
  5. NHS Paper summarising Patient experience Framework (2011). Gateway reference 17273.
  6. Goldberg, E. and Beitz, J. (2010) The Lived Experience of Diverse Elders With Chronic Wounds. Ostomy Wound Management. Volume 56, issue 11, pp. 36-46.